# Seres Therapeutics, Inc. (MCRB) · Edgar & Edgarette company card

> Seres Therapeutics (MCRB) reported revenue of $1 million in FY2025, operating margin -11910% against a -3.8% median for pharmaceutical preparations, equity 32.0% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1609809 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/MCRB) · [JSON](https://www.pops4.com/boards/company/MCRB.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $789,000 |
| Revenue growth, 1 year | — |
| Revenue growth per year | -72.8% |
| Operating margin | -11910.1% (prior year -Infinity%) |
| Net margin | 721.9% |
| Operating cash flow | $1M |
| Capital spending | $252,000 |
| Free cash flow | $865,000 |
| Cash | $46M |
| Long-term debt | — |
| Total assets | $138M |
| Total equity | $44M |
| Equity ÷ assets | 32.0% |
| Return on equity | 12.9% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -25.59 (distress zone)
- Piotroski F: 6 of 9 (solid)
- Health Harbor boat: Sound ship · one warning sign · revenue is hard to predict: its 80% range is ±28%

## Edgarette's reading

Exposure: revenue $789K (FY2025). Experience: one year on record, down 72.8% a year over 4 years; operating margin -11910.1%, up from null. Soundness: equity 32.0% of assets, return on equity 12.9%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $278K and $499K next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -11910.1% against a -3.8% median.

Range logged 2026-10-27, receipt 01d4449b6e6aeac1, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 4, latest 2026-10-26 ([filing](https://www.sec.gov/Archives/edgar/data/1609809/000119312526432004/0001193125-26-432004-index.htm))

## Recent filings

- 8-K · filed 2026-10-26 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/1609809/000119312526432004/0001193125-26-432004-index.htm)
- 10-Q · filed 2026-08-05 · [filing](https://www.sec.gov/Archives/edgar/data/1609809/000119312526334174/0001193125-26-334174-index.htm)
- 8-K · filed 2026-08-05 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1609809/000119312526333820/0001193125-26-333820-index.htm)
- 8-K · filed 2026-08-04 · 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1609809/000119312526332742/0001193125-26-332742-index.htm)
- 8-K · filed 2026-07-08 · 5.02 Departure or Election of Directors; Appointment of Officers; 5.07 Submission of Matters to a Vote of Security Holders; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1609809/000119312526298525/0001193125-26-298525-index.htm)
- 8-K · filed 2026-07-08 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1609809/000119312526298005/0001193125-26-298005-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001609809.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1609809

## Cite

POPS4, Edgar & Edgarette: Seres Therapeutics, Inc. (MCRB) company card, from the company's own SEC filings, accessed 2026-10-27, https://www.pops4.com/boards/company/MCRB. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.